Screener
Aclaris Therapeutics ACRS Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by Aclaris Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-092065
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable | $15,516 | $13,158 |
| Accrued expenses | 5,959 | 8,791 |
| Deferred income | 3,976 | 3,943 |
| Other current liabilities | 2,790 | 2,753 |
| Total current liabilities | 28,241 | 28,645 |
| Other liabilities | 1,262 | 1,565 |
| Deferred income, net of current portion | 14,309 | 16,168 |
| Contingent consideration | 11,300 | 11,000 |
Item 1. Financial Statements
FAQ
- What is Aclaris Therapeutics's accrued expenses?
- Aclaris Therapeutics (ACRS) reported accrued expenses of $2.79M in Q2 2026.
- How has Aclaris Therapeutics's accrued expenses changed year-over-year?
- Aclaris Therapeutics's accrued expenses increased by 2.7% year-over-year, from $2.72M to $2.79M.
- What is the long-term trend for Aclaris Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), Aclaris Therapeutics's accrued expenses has grown at a 35.5% compound annual growth rate (CAGR), from $603K to $2.75M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.
Ask your AI about Aclaris Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude